12:00 AM
 | 
Dec 14, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Midostaurin: Phase III data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Product: Midostaurin ( PKC412, CGP 41251)
Business: Cancer
Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135); Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117)
Description: FMS-like tyrosine kinase 3 (FLT3; CD135) and stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117) inhibitor...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >